



## Announcement Summary

**Entity name**

TELIX PHARMACEUTICALS LIMITED

**Date of this announcement**

Friday May 08, 2026

**The +securities the subject of this notification are:**

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

**Total number of +securities to be issued/transferred**

<b>ASX +security code</b>	<b>Security description</b>	<b>Total number of +securities to be issued/transferred</b>	<b>Issue date</b>
TLXAZ	SHARE RIGHTS US	25,000	04/05/2026
TLXAO	SHARE APPRECIATION RIGHTS	2,338,411	04/05/2026
TLXAW	PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	4,444,826	04/05/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ACN

**Registration number**

616620369

**1.3 ASX issuer code**

TLX

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

8/5/2026



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

**ASX +security code and description**

TLXAO : SHARE APPRECIATION RIGHTS

**Date the +securities the subject of this notification were issued**

4/5/2026

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Darren Smith	Darren Smith	200,056
David Cade	David Cade	152,851

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

Refer to Telix Equity Incentive Plan Rules (available at <https://ir.telixpharma.com/governance/documents-charters>) and the Remuneration report within the Telix 2025 Annual Report (available at <https://ir.telixpharma.com/reports>).

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Performance Share Appreciation Rights (PSARs) (exercise price: A\$10.86) granted to Telix employees ex-US as 2026 Long Term Incentive. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2026-2028, and a two year exercise period following vesting. For further details refer to the Remuneration report in Telix's 2025 Annual Report (available at <https://ir.telixpharma.com/reports>).

Issue details

**Number of +securities**

2,338,411

**ASX +security code and description**

TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025

**Date the +securities the subject of this notification were issued**

4/5/2026

**Will these +securities rank equally in all respects from their issue date with the existing issued**

**+securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Darren Patti	Darren Patti	188,180

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

Refer to Telix Equity Incentive Plan Rules (available at <https://ir.telixpharma.com/governance/documents-charters>) and the Remuneration report within the Telix 2025 Annual Report (available at <https://ir.telixpharma.com/reports>).

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Performance Share Appreciation Rights (PSARs) (exercise price: US\$11.15) granted to Telix employees as 2026 Long Term Incentive. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan Rules, with a measurement period of 2026-2028, and a two year exercise period following vesting. For further details refer to the Remuneration report in Telix's 2025 Annual Report (available at <https://ir.telixpharma.com/reports>).  
Rights over Telix ordinary shares to be delivered as Americal Depository Shares to US domiciled employees.

## Issue details

**Number of +securities**

4,444,826

**ASX +security code and description**

TLXAZ : SHARE RIGHTS US

**Date the +securities the subject of this notification were issued**

4/5/2026

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

No

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

Refer to Telix Equity Incentive Plan Rules (available at <https://ir.telixpharma.com/governance/documents-charters>) and the Remuneration report within the Telix 2025 Annual Report (available at <https://ir.telixpharma.com/reports>).

**Any other information the entity wishes to provide about the +securities the subject of this notification**

A total of 25,000 zero-priced retention share rights were issued in equal tranches:  
- tranche 1, restricted to 1 November 2028 (3 year retention), subject to testing on 1 November 2028;  
- tranche 2, restricted to 1 November 2029 (4 year retention), subject to testing on 1 November 2029.



Exercise period: automatic exercise at the end of the restriction period.  
Rights over Telix ordinary shares to be delivered as American Depositary Shares to US domiciled employees.

Issue details

---

**Number of +securities**

25,000

---



## Part 4 - +Securities on issue

**Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLX : ORDINARY FULLY PAID	339,113,888

**4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLXAY : DEFERRED SHARE RIGHTS	66,140
TLXAX : DEFERRED SHARE RIGHTS EX-US	60,528
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAZ : SHARE RIGHTS US	409,500
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,289,754
TLXAO : SHARE APPRECIATION RIGHTS	15,755,683
TLXAT : CONVERTIBLE NOTES	6,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	175,000
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	9,450
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	8,720,528
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

Yes

**5.1a Select the number of the applicable exception in Listing Rule 7.2**

13